The Canadian government has pledged a total of $89.9 million to two biotech companies: Quebec’s Aramis Biotechnologies and Alberta’s Providence Therapeutics. Aramis, which inherited intellectual property from Medicago, will apply $40 million to advance plant-based influenza vaccine production. Meanwhile, Providence Therapeutics, which was working on mRNA technology, will receive $49.9 million to enhance biomanufacturing and R&D in mRNA medicines.
The two firms, both backed by the government’s Strategic Innovation Fund, had worked on but ultimately failed to deliver a medicine in response to the Covid-19 outbreak.
Want to know more? Check out the source code here.